Joseph Bernardo joins Rarity Bioscience

Mr. Joe Bernardo joins Rarity Bioscience as a private investor in a recent funding round. Additionally, he will take on the role of Strategic Business Advisor to the board, with a primary focus on commercialization, partnerships, and expanding into the US market.

Innovations in MRD Detection and Improved Sensitivity

Joe Bernardo shared his excitement about Rarity Bioscience’s innovative technology and market readiness, highlighting the improved sensitivity for detecting minimal residual disease (MRD), its applicability across multiple cancer types, and the use of existing clinical automation, eliminating the need for costly new analyzers.

"Investing in Rarity Bioscience was an easy choice just considering their logarithmic improvement in sensitivity for detecting minimal residual disease (MRD). The market is becoming ripe for MRD, and their solution stands out by leveraging analyzers and automation already present in clinical settings, eliminating the need for capital intensive market development of unique analyzers. Additionally, their regent based, plug-and-play solution is applicable across multiple cancer types, fitting seamlessly and elegantly into the existing ecosystem, an often underestimated element for commercial success."

Background at Linden Capital Partners

Joseph Bernardo is currently Operating Partner at Linden Capital Partners, a Chicago based private equity firm specialized in Healthcare, as well as board chairman at StatLab. He has previously held several senior operational positions in life science and the diagnostic industry, including President at Next Gen Sequencing and Oncology at Thermo Fisher Scientific, SVP Lab Business at Siemens, as well as several board and advisory positions including, BioIVT, Boston Consulting Group, Chairman at SeraCare, Mobidiag, and Board Chairman at Lunaphore.  

“Having Joe onboard as an advisor is a great addition to the company, especially considering future US market entry. I really appreciate his straightforward business approach, much of the American boldness that Swedish companies often lack.“ – Linus Bosaeus, CEO Rarity 

This is not the first time for Joe in an Uppsala company, during his time at Thermo Fisher he spent over three years as President at IDD (former Phadia) in Uppsala.  

“Having worked with Joe at my time at Thermo Fisher, I have seen his capacity and brilliance up front, truly a force that propels business to the next level.” – Per Matsson, Board Chairman Rarity

Share this article

Recommended articles